Document is current

Article History

Received: 16 October 2024

Accepted: 31 December 2024

First Online: 12 January 2025

Declarations

:

: This study was approved by the Institutional Review Board for Clinical Research of Kansai Medical University Medical Center (2022275). Informed consent was obtained via the questionnaire from the experts regarding their participation in the research, provision of research-related information, protection of personal information, management of information, and disclosure of information regarding the research.

: Not applicable.

: The authors declare that they have no competing interests. We have had the following interests over the past three years: YT has received grant funding from the Japan Society for the Promotion of Science and speaker’s honoraria from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Eisai, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, UCB Japan, Novartis, Teijin Pharma, Nippon Boehringer Ingelheim, and Mitsubishi Tanabe Pharma. TS received grant funding from Shionogi & Co., Ltd. and speaker’s honoraria from EA Pharma Co. Ltd., Otsuka, Lundbeck, Merck Sharp & Dohme, Sumitomo Pharma, Takeda Pharmaceutical, and Tsumura & Co. KY has received speaker honoraria from Sumitomo Pharma, Otsuka, Eisai, and Viatris. WO received grant funding from the Japan Society for the Promotion of Science and speaker honoraria from Otsuka, Viatris, and BioGaia. HK has received speaker honoraria from Otsuka, Sumitomo Pharma, and Lundbeck in Japan. NK has received speaker honoraria from Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, and MSD. TT received a grant from the Japan Society for the Promotion of Science and honorariums from Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomiyakuhin, Sumitomo Pharma, Kyowa Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Mylan EPD, Mitsubishi Tanabe Pharma, Viatris, Mochida Pharmaceutical, Janssen Pharmaceutical, TEIJIN PHARMA, and Lundbeck, Japan. TN received research grant funding from the Japan Agency for Medical Research and Development (23fk0108586s0101 and 24dk0307125h0001), Senshin Medical Research Foundation, XNef, and Inter Reha and speaker honoraria from EA Pharma, Janssen, Lundbeck, MSD, Otsuka, Sumitomo, and Takeda. NA has received grant funding from the Japan Society for the Promotion of Science and speaker’s honoraria from Meiji-Seika Pharma, Lundbeck, and Sumitomo Pharma outside the submitted work. KW has received speaker honoraria from Sumitomo Pharma, Otsuka, Eisai, Takeda Pharmaceutical, MSD, Viatris, and Mitsubishi Tanabe Pharma. Ken Inada received personal fees from Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Nipro, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Yoshitomiyakuhin, Viatris, and he received research grant support from Mochida, Otsuka and Sumitomo pharma in the last three years. MT received grant funding from Japan Society for the Japan Society for the Promotion of Science, Otsuka, Eisai, and Daiichi-Sankyo, and honoraria of speakers and chairpersons from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Eisai, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, and Teijin Pharma.